EUVIMEDEUVIMED entdecken
LeitlinieOpen Access

Impact of Society Guidelines on Trends in Use of Newer P2Y 12 Inhibitors for Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention

Mohamed O Mohamed iD, Evangelos Kontopantelis iD, Mirvat Alasnag iD, Leila Abid iD, Amitava Banerjee iD, Andrew S P Sharp iD, Christos Bourantas iD, Alex Sirker, Nick Curzen iD, Mamas A Mamas iD

Journal of the American Heart Association · 2024

DOI: 10.1161/jaha.124.034414 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Journal of the American Heart Association, 2024. Verfasst von Mohamed O Mohamed und 9 weiteren Autor:innen. Beteiligte Einrichtung: Keele Cardiovascular Research Group, Centre for Prognosis Research Keele University Stoke-on-Trent United Kingdom. Hauptthemen laut MEDLINE: Acute Coronary Syndrome, Percutaneous Coronary Intervention, Purinergic P2Y Receptor Antagonists, Practice Guidelines as Topic. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 19 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background Over the past decade, major society guidelines have recommended the use of newer P2Y 12 inhibitors over clopidogrel for those undergoing percutaneous coronary intervention for acute coronary syndrome. It is unclear what impact these recommendations had on clinical practice. Methods and Results All percutaneous coronary intervention procedures (n=534 210) for acute coronary syndrome in England and Wales (April 1, 2010, to March 31, 2022) were retrospectively analyzed, stratified by choice of preprocedural P2Y 12 inhibitor (clopidogrel, ticagrelor, and prasugrel). Multivariable logistic regression models were used to examine odds ratios of receipt of ticagrelor and prasugrel (versus clopidogrel) over time, and predictors of their receipt. Overall, there was a significant increase in receipt of newer P2Y 12 inhibitors from 2010 to 2020 (2022 versus 2010: ticagrelor odds ratio, 8.12 [95% CI, 7.67–8.60]; prasugrel odds ratio, 6.14 [95% CI, 5.53–6.81]), more so in ST‐segment–elevation myocardial infarction than non–ST‐segment–elevation acute coronary syndrome indication. The most significant increase in odds of receipt of prasugrel was observed between 2020 and 2022 ( P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Acute Coronary SyndromePercutaneous Coronary InterventionPurinergic P2Y Receptor AntagonistsPractice Guidelines as TopicTicagrelorPrasugrel HydrochlorideClopidogrelHumansMaleFemaleAgedMiddle AgedRetrospective StudiesWalesPlatelet Aggregation InhibitorsPractice Patterns, Physicians'EnglandGuideline AdherenceST Elevation Myocardial InfarctionNon-ST Elevated Myocardial InfarctionTime FactorsTreatment Outcome

Stichwörter der Autor:innen

acute coronary syndromenewer P2Y12 inhibitorsoutcomespercutaneous coronary interventiontrends

Substanzen

Purinergic P2Y Receptor AntagonistsTicagrelorPrasugrel HydrochlorideClopidogrelPlatelet Aggregation Inhibitors

Autor:innen und Institutionen

  • Keele Cardiovascular Research Group, Centre for Prognosis Research Keele University Stoke-on-Trent United Kingdom.
  • Institute of Health Informatics University College London London United Kingdom.
  • Barts Heart Centre St. Bartholomew's Hospital London United Kingdom.
  • Division of Informatics, Imaging and Data Sciences, School of Health Sciences, Faculty of Biology, Medicine and Health, Manchester Academic Health Science Centre (MAHSC) University of Manchester United Kingdom.
  • Cardiac Center King Fahd Armed Forces Hospital Jeddah Saudi Arabia.
  • Hedi Chaker University Hospital Sfax Tunisia.

ORCID-Profile: Mohamed O Mohamed, Evangelos Kontopantelis, Mirvat Alasnag, Leila Abid, Amitava Banerjee, Andrew S P Sharp, Christos Bourantas, Nick Curzen, Mamas A Mamas

Zitieren

APA

Mohamed, M. O., Kontopantelis, E., Alasnag, M., Abid, L., Banerjee, A., Sharp, A. S. P., Bourantas, C., Sirker, A., Curzen, N., & Mamas, M. A. (2024). Impact of Society Guidelines on Trends in Use of Newer P2Y 12 Inhibitors for Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. Journal of the American Heart Association. https://doi.org/10.1161/jaha.124.034414

Vancouver

Mohamed MO, Kontopantelis E, Alasnag M, Abid L, Banerjee A, Sharp ASP, et al. Impact of Society Guidelines on Trends in Use of Newer P2Y 12 Inhibitors for Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention. Journal of the American Heart Association. 2024. doi:10.1161/jaha.124.034414

BibTeX
@article{Mohamed2024,
  author = {Mohamed, Mohamed O and Kontopantelis, Evangelos and Alasnag, Mirvat and Abid, Leila and Banerjee, Amitava and Sharp, Andrew S P and Bourantas, Christos and Sirker, Alex and Curzen, Nick and Mamas, Mamas A},
  title = {Impact of Society Guidelines on Trends in Use of Newer P2Y 12 Inhibitors for Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention},
  journal = {Journal of the American Heart Association},
  year = {2024},
  doi = {10.1161/jaha.124.034414}
}
Kostenlos starten →